Stanford Medicine Radiology Awarded Up to $35 million from ARPA-H to Advance Precision Cancer Imaging and Therapy
September 19, 2024
Related Articles
CHMP Offers Positive Opinion for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS
The EMA’s CHMP has recommended the approval of imetelstat for transfusion-dependent anemia in lower-risk myelodysplastic syndrome.
Brigatinib Plus Local Consolidative Therapy Shows Promise in ALK+ NSCLC
During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ lung cancer in the first article…
100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Solid Pseudopapillary Tumor of the Pancreas: Is Enucleation Safe?
Annals of Surgical Oncology – While solid pseudopapillary tumor (SPT) of the pancreas are oncologically low-risk tumors, their resection with pancreaticoduodenectomy (PD) or partial pancreatectomy…
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…
Unlocking the Potential of Patient Navigation: New CPT Codes Pave the Way for Enhanced Oncology Care
Explore the 2024 CPT codes for oncology patient navigation and how pharma can support improved patient outcomes.
Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
New-Onset Diabetes and Pancreatic Cancer: An Important Link
Pancreatic cancer is a tough disease to catch early because it doesn’t always cause clear symptoms right away. Still, noticing changes in your body can…
